Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the clinical events of the patients with acute cerebral large vessel occlusion or stenosis and atrial fibrillation, treated by apixaban within 14 days after onset. This is the observational study that patients will be made the registration at the timing of both retrospective period and prospective period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hyogo College of Medicine
• Treatments: Apixaban

Criteria

Inclusion Criteria:

1. Patients 20 years and older with acute stroke and treated with oral apixaban within 14 days after onset.

2. Patients who are hospitalized in a period from Oct 1, 2014 to Feb 28, 2018

3. Patients with acute cerebral large vessel occlusion or stenosis (> 50%)

4. Patients with non-valvular atrial fibrillation

5. Patients who are not confirmed ICH by MRI or CT within 24 hours after r-tPA infusion.

Exclusion Criteria:

1. Patients who are considered to be ineligible for the study participation by the investigator.

2. Patients who are pregnant or potentially pregnant.

3. Patients who have a history of hypersensitivity to apixaban

4. Patients with hepatic disease having coagulation disorder and clinically important bleeding risk

5. Patients with renal failure (creatinine clearance < 15 mL/min) 6）Patients with Active pathological bleeding including intracranial bleeding of any type